• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Royalty Deal Could Be A Big Development For BioMarin Stock (BMRN)

    Simply Wall St·09/08/2026 12:22:40
    Listen to the news
    • Ascendis Pharma announced a past global settlement and license agreement with BioMarin Pharmaceutical covering YUVIWEL and navepegritide products. The agreement includes worldwide non-exclusive rights and royalty obligations of 20% in the US and 18% in the EU, South Korea, and Brazil through May 20, 2030.
    • For BioMarin Pharmaceutical, long-dated royalties on navepegritide related sales convert an intellectual property dispute into a recurring revenue source while clearing litigation and regulatory friction.
    • We will now look at how this royalty-based settlement with Ascendis Pharma affects BioMarin Pharmaceutical's broader investment narrative.

    Scan how BioMarin Pharmaceutical’s royalty deal fits alongside other potential royalty and cash flow stories by reviewing our curated list of 17 high quality undiscovered gems.

    BioMarin Pharmaceutical Investment Narrative Recap

    Owning BioMarin Pharmaceutical means believing its rare disease portfolio and late stage pipeline can support steady product demand while management keeps spending in check. The key near term swing factor remains execution on therapies like VOXZOGO and other high value treatments, because current net margin of 2.1% leaves little room for error if pricing pressure or reimbursement pushback intensifies. The Ascendis settlement converts a legal dispute into royalty income and removes regulatory friction, but it does not materially change the core operational question around whether future launches can offset rising R&D and SG&A costs.

    The new royalty license with Ascendis matters most when viewed alongside BioMarin Pharmaceutical's push to broaden its rare disease footprint through projects such as BMN 333 and the Inozyme acquisition. The agreement confirms BioMarin is willing to monetize intellectual property where it is not the direct commercial driver, while focusing internal resources on lead programs that carry larger potential patient pools. That trade off can support a more diversified mix of cash flows, but the benefit still depends on successful clinical outcomes, smooth integration of acquired assets, and disciplined cost control as trials move toward pivotal stages.

    Even so, there is one operational weak spot that keeps coming up once you look past the new royalty stream and into ...

    Read the full BioMarin Pharmaceutical narrative to see the case behind these numbers.

    BioMarin Pharmaceutical's narrative projects US$5.0b revenue and US$1.3b earnings by 2029. This assumes 14.0% yearly revenue growth and requires earnings to rise by about US$1.2b from US$73.0m today.

    BioMarin Pharmaceutical's forecasts put fair value at $91.42 versus the $66.53 share price, indicating a 37% difference from its current price that could narrow quickly.

    NasdaqGS:BMRN 1-Year Stock Price Chart
    NasdaqGS:BMRN 1-Year Stock Price Chart

    Exploring Other Perspectives

    Some of the most optimistic analysts focus on BioMarin Pharmaceutical's operating leverage rather than competition risk. Before this royalty deal, the bullish camp was modeling revenue of about US$5.5b and earnings near US$2.1b by 2029. This new settlement could nudge those views; treat it as a useful prompt to compare different forecasts.

    If you want to see how other investors are pricing the story, compare these assumptions against 3 other fair value estimates for BioMarin Pharmaceutical.

    Decide For Yourself

    Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

    Looking for more BioMarin Pharmaceutical style investment ideas?

    If this BioMarin Pharmaceutical review has sharpened your sense of what you want in a business, you can use that as a filter and apply it across the wider market. The Simply Wall St Screener can help you quickly surface other stocks that match the mix of quality, resilience, or income you are looking for.

    • For investors who care most about valuation discipline and quality fundamentals, you can start with a focused set of 49 high quality undervalued stocks that align with that mindset.
    • If capital preservation and resilience matter more to you than absolute upside, you might consider screening for 83 resilient stocks with low risk scores that keep balance sheets and risk scores front of mind.
    • Income driven investors who want yield alongside robust financial footing can focus on our curated 6 dividend fortresses that combine higher payouts with stability.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.